Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amgen (NQ: AMGN )

262.23 -1.98 (-0.75%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Amgen

< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
44 45 Next >
7 Best Pharmaceutical Stocks to Buy Now
These investments represent the best pharmaceutical stocks. Each offers incredible upside potential in the post-pandemic world. 
Via InvestorPlace
HC Wainwright Is Bullish On DICE Therapeutics - Read Why
Via Benzinga
Biotech Hasn't Been This Blazing Hot Since Early 2021 — Here Are The Top 5
The group has several commonalities, including strong ratings and promising charts. 
Via Investor's Business Daily
3 Biotech Stocks Outperforming a Bear Market
These biotech stocks are the most attractive from a valuation and growth perspective as they are less impacted by a slowing economy or change in monetary policy. 
Via InvestorPlace
Amgen Touts Early Lumakras Combo Data In KRAS Cancer Settings
BMO Capital Markets says that while Amgen Inc's (NASDAQ: AMGN) Lumakras (sotorasib) + PD1i data was delayed to the August 7 presentation, it did get data on the Lumakras + SHP2 inhibitor combination.  
Via Benzinga
Can-Fite BioPharma Shares Jump After Piclidenoson Data In Psoriasis Trial
Via Benzinga
Looking Into Amgen's Recent Short Interest
Amgen's (NASDAQ:AMGN) short percent of float has fallen 6.92% since its last report. The company recently reported that it has 17.22 million shares sold short, which is 3.23% of... 
Via Benzinga
Amgen Whale Trades For July 12
Someone with a lot of money to spend has taken a bearish stance on Amgen (NASDAQ:AMGN). And retail traders should know. We noticed this today when the big position showed up on publicly available... 
Via Benzinga
The Next CRISPR Is Here: How Verve Plans To Rival Amgen, Regeneron In Cholesterol
This could offer an improvement over CRISPR, which requires cutting DNA. 
Via Investor's Business Daily
Here's How Much You Would Have Made Owning Amgen Stock In The Last 10 Years
Amgen (NASDAQ:AMGN) has outperformed the market over the past 10 years by 1.22% on an annualized basis producing an average annual return of 12.18%. Currently, Amgen has a market capitalization of... 
Via Benzinga
Pharma Rally Continues As Pfizer, Amgen Look To Break Out, Pulling Rivals With Them
Four pharmaceutical stocks, including three biotech movers, are making big moves. 
Via Investor's Business Daily
Check Out What Whales Are Doing With AMGN
Someone with a lot of money to spend has taken a bearish stance on Amgen (NASDAQ:AMGN). And retail traders should know. We noticed this today when the big position showed up on publicly available... 
Via Benzinga
Biotech Stocks To Watch And Pharma Industry News
Track the latest trends and leading stocks in the biotech and pharmaceutical industries. 
Via Investor's Business Daily
How To Make Money In This Bear Market
To the astute and disciplined value investor, bear markets bring opportunity, and more to the point, safety. 
Via Talk Markets
Biotechs Say ESG Is Core To Their Mission; Do Investors Believe Them?
The biotech industry is trying to catch the ESG investing bug. But that doesn't mean investors are giving it credit, executives say. 
Via Investor's Business Daily
The 3 Best Retirement Stocks for Gen-Z Investors
Older generations are showing their worry and providing a huge opportunity in the market's best retirement stocks for Gen-Z investors to buy 
Via InvestorPlace
Is Pfizer Stock A Buy Or A Sell As Its Covid Vaccine Faces A New Lawsuit?
The FDA's advisors recently backed Pfizer's Covid shot for young children. 
Via Investor's Business Daily
Only 8 Of The 30 Dow Jones Stocks Were Positive In The First Half Of 2022: Chevron Leads, But Who Else Was Up?
The U.S. stock market had a rough start to 2022 with a market correction hitting stocks and many indexes seeing their worst performances in decades. 
Via Benzinga
Here Are The 5 Best Dow Jones Stocks So Far This Year Amid Market Sell-Off
Chevron is well off its June peak, but still the top blue chip stock this year. 
Via Investor's Business Daily
Scanning for opportunities
Markets stabilized yesterday. Implied volatilities were steady on the day with the front-end remarking slightly higher while the back-end was unchanged. 
Via Talk Markets
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Peering Into Amgen's Recent Short Interest
Amgen's (NASDAQ:AMGN) short percent of float has risen 7.63% since its last report. The company recently reported that it has 20.30 million shares sold short, which is 3.81% of... 
Via Benzinga
$100 Invested In Amgen 15 Years Ago Would Be Worth This Much Today
Amgen (NASDAQ:AMGN) has outperformed the market over the past 15 years by 3.97% on an annualized basis producing an average annual return of 10.41%. Currently, Amgen has a market capitalization of... 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
7 Dividend Stocks to Buy for Your Grandkids
If this roiling market is making you seasick, then it's an excellent time to batten down the hatches with these reliable dividend stocks. 
Via InvestorPlace
We're Looking At Obesity In A New Way — And 4 Pharmaceutical Stocks Could Benefit
The conversation around obesity is changing. Two diabetes drug makers are at the forefront. 
Via Investor's Business Daily
How Is The Market Feeling About Amgen?
Amgen's (NASDAQ:AMGN) short percent of float has fallen 5.35% since its last report. The company recently reported that it has 18.85 million shares sold short, which is 3.54%... 
Via Benzinga
7 of the Hottest ETFs to Buy Right Now
These are the hottest ETFs to buy in June whether you're looking for discounts or ETFs that are already on the move. 
Via InvestorPlace
$100 Invested In Amgen 20 Years Ago Would Be Worth This Much Today
Amgen (NASDAQ:AMGN) has outperformed the market over the past 20 years by 2.03% on an annualized basis producing an average annual return of 9.14%. Currently, Amgen has a market capitalization of... 
Via Benzinga
The Surprising Way Mirati Therapeutics Is Angling To Rival Amgen — And Could Succeed
Mirati Therapeutics said a combination using its KRAS drug appeared promising. 
Via Investor's Business Daily
< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
44 45 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.